Mirador Therapeutics

Biotech & Life Sciences · San Diego, United States · Founded 2024

A next-generation precision medicine company focused on immunology and inflammation MoreLess

Mirador Therapeutics is a pioneering company in the field of precision medicine, focusing on immune-mediated inflammatory and fibrotic diseases. The company leverages advanced biology, multi-modal data, and sophisticated analytics to develop transformational therapies aimed at improving patient outcomes. Founded by former executives of Prometheus Biosciences, which was acquired by Merck for $10.8 billion, Mirador Therapeutics operates in the biotechnology sector. Its business model revolves around the development and commercialization of precision therapies, targeting healthcare providers and patients suffering from immune-mediated conditions. Revenue is generated through the sale of these specialized treatments and potential partnerships with larger pharmaceutical companies.

Keywords: precision medicine, immunology, inflammation, fibrotic diseases, advanced analytics, biotechnology, healthcare, patient outcomes, transformational therapies, Prometheus Biosciences.

Valuation $1–2.5B

Headcount <100

Total funding $500M–1B

Unlock exact values

Company overview

Mirador Therapeutics company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2024
Headquarters: San Diego, United States
Employees: 95
Open positions: 2
Dealroom signal: 92.8

Website ↗LinkedIn ↗

client focusb2btechnologyBig Datasub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorPrecision MedicinesectorRumoured $1BsectorBiotech and PharmasectorDT and LSsectorscience-based

Valuation & funding

Mirador Therapeutics funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES BOther financing	Jan 2026	$250M	$2B	Farallon Capital Management · Fidelity Investments · ARCH Venture Partners · OrbiMed	↗
SERIES AOther financing	Mar 2024	$400M	$1.6B	Farallon Capital Management · ARCH Venture Partners · OrbiMed · Point72 Ventures	↗

Showing 2 recorded eventsUnlock the complete deal history →

Growth signals

Mirador Therapeutics website traffic

Latest recorded traffic for Mirador Therapeutics is 7.2K monthly website visits, up 20% over the last three months. Mirador Therapeutics's team grew 4.4% over the past year.

Latest monthly visits7.2K 3-month web change+20% 1-year team growth+4.4%

Monthly website visits29 observations · Mar 2024–Jul 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Hiring

Open positions at Mirador Therapeutics

Current openings linked to this company in Dealroom.

Director, ImmunologySan Diego, California, United States, Northern America, Americas · Other · Aug 27, 2026 Director, Immunology - San Diego, CASan Diego, CA · Other · Aug 27, 2026 Senior Manager, CMC – Manufacturing and R&D - San Diego, CASan Diego, California, United States, Northern America, Americas · Other · Aug 24, 2026 Executive Director, Investor Relations - San Diego, CASan Diego, California, United States, Northern America, Americas · Finance · Aug 24, 2026 Scientist, Translational Genomics - San Diego, CASan Diego, California, United States · Other · Jan 22, 2026

5 distinct openings shownExplore hiring signals →

Comparisons

Mirador Therapeutics compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAntares TherapeuticsDevelopment of precision oncology therapies, utilizing acquired discovery capabilities and a validated pipeline for patient treatments	Boston, United States	Operational	102	$177M	$708M
OTOdyssey TherapeuticsBuilding a machine learning-based platform to develop novel therapeutics focusing on cancer and autoimmune diseases	Boston, United States	Operational
LBLeo Summit BiotechnologyCreating a characteristic research and development platform combining "engineering center + expert think tank + postdoctoral workstation" combining production, learning and research	China	Operational
EVevidnetProvides evidence-based medicine to patients	Seoul, South Korea	Operational
DRDrugBankAI-powered pharmaceutical knowledge platform for drug development	Edmonton, Canada	Operational
PRPredxBioTissue-Based Decision Intelligence for Oncology	Bellevue, United States	Operational
CSCaris Life SciencesA profiling platform that identifies novel molecular targets to inform and enhance drug development and advanced diagnostics	Irving, United States	Operational
INInflammatixDeveloping novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system	Sunnyvale, United States	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Mirador Therapeutics's talent

Book a demo to see the people

Team profiled 4 named & role-tagged

Founders /100 quality score

Key operators 3 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

20 investors on Mirador Therapeutics's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 20 investors entered at this stage

Farallon Capital Management

ARCH Venture Partners

OrbiMed

Point72 Ventures

Alexandria Venture Investments

RTW Investments

Woodline Partners

Fairmount Funds Management

Blue Owl Capital

Fidelity Investments

Invus

Sanofi Ventures

Boxer Capital

Logos Capital

Moore Strategic Ventures

TCGX

Venrock Healthcare Capital Partners

Fairmount Partners

Adage Capital

T. Rowe Price

Global footprint

Where Mirador Therapeutics has talent and traffic

Workforce by country

3 countries with
team presence

🇺🇸 United States97.4%

🇳🇱 Netherlands1.3%

🇸🇬 Singapore1.3%

3 countries shown

In the news

Latest news about Mirador Therapeutics

Recent press, funding announcements, and product moves mentioning Mirador Therapeutics — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Mirador Therapeutics

An AI-synthesized read of the highest-engagement posts about Mirador Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mirador Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.